Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead SciencesFRA:GIS +1.82%74 EV-to-EBITDA is 120.51 as of Aug. 19, 2026, which is 942% above its 10-year median of 11.56. GuruFocus rates FRA:GIS with a GF Score™ of 74/100 and a GF Value™ of €92.53 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 734 Drug Manufacturers companies, Gilead Sciences ranks worse than 95.91% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gilead Sciences's enterprise value is €173,404 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1,439 Mil. Therefore, Gilead Sciences's EV-to-EBITDA for today is 120.51.
The historical rank and industry rank for Gilead Sciences's EV-to-EBITDA or its related term are showing as below:
FRA:GIS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3 Med: 11.56 Max: 111.64
Current: 111.39
During the past 13 years, the highest EV-to-EBITDA of Gilead Sciences was 111.64. The lowest was 5.30. And the median was 11.56.
FRA:GIS's EV-to-EBITDA is ranked worse than 95.91% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs FRA:GIS: 111.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gilead Sciences's PE Ratio (TTM) for today is calculated as:
Gilead Sciences's share price for today is €120.98.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.386.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Gilead Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GIS vs PFE, BMY, AMGN: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's EV-to-EBITDA falls into.
Gilead Sciences's current Enterprise Value is €173,404 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (FRA:GIS) has a EV-to-EBITDA of 120.51 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gilead Sciences. This is 942% above median its historical median of 11.56. Over the past decade, Gilead Sciences' EV-to-EBITDA has ranged from 5.30 to 111.64. According to the industry distribution chart, Gilead Sciences ranks #704 out of 734 companies in the Drug Manufacturers industry, placing it in the top 95.9%.
Is Gilead Sciences' EV-to-EBITDA too high?
Gilead Sciences' current EV-to-EBITDA of 120.51 is 942% above median its 10-year median of 11.56. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 111.64. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Gilead Sciences' value of 120.51 is 804.4% above this industry median. Based on the distribution chart, Gilead Sciences ranks #704 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gilead Sciences has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' EV-to-EBITDA compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #704 out of 734 companies for EV-to-EBITDA. This places Gilead Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Gilead Sciences' value of 120.51 is 804.4% above this benchmark. Historically, Gilead Sciences' own EV-to-EBITDA has ranged from 5.30 to 111.64 over the past decade. While the company's 10-year median is 11.56 vs. the industry median of 13.33, Gilead Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current EV-to-EBITDA of 120.51 is 804.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Gilead Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current EV-to-EBITDA is 120.51, which is 942% above median its own 10-year median of 11.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (FRA:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €92.53, compared to a current price of €120.98 — trading 30.7% above its estimated fair value. The current EV-to-EBITDA is 120.51, which is 942% above median its 10-year median of 11.56 and 804.4% above the Drug Manufacturers industry median of 13.33. Gilead Sciences' overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Gilead Sciences (FRA:GIS), the current EV-to-EBITDA is 120.51 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (FRA:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €120.98 is trading 30.7% above its estimated GF Value™ of €92.53.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for FRA:GIS:
EV-to-EBITDA: 120.51 (942% above median its 10-year median of 11.56)
GF Value™: €92.53 vs. price of €120.98 (30.7% above fair value)
Industry Position: 804.4% above the Drug Manufacturers median (#704 of 734)
No single metric tells the full story. See the FRA:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
74GF Score
Get the complete analysis for FRA:GIS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GIS has been successfully added to your 
